August 17, 2026 at 10:16 AM 2 min readhealthDaily Pulse
CDSCO Streamlines Approval Process for Unapproved New Drugs
The Investigational New Drug Division in New Delhi will comprehensively evaluate novel drug applications under updated rules.
[Regulatory Clarification on Unapproved Drugs]:
The Central Drugs Standard Control Organization issued a significant clarification regarding the processing of applications for new drugs that have not yet received approval anywhere else in the world. Specifically, applications for importing and marketing such drugs, where Phase III Global Clinical Trials involving Indian subjects are ongoing or completed, will be comprehensively evaluated and processed by the Investigational New Drug Division at CDSCO Headquarters in New Delhi.
[Recent Pharmaceutical Product Approvals]:
Alongside this structural regulatory update, recent drug approvals by CDSCO include Gabapentin as a bulk drug, and BIO Biphasic Isophane Insulin Injection IP for the treatment of diabetes mellitus, both approved on August 10, 2026. Additionally, Esaxerenone as a bulk drug and Tedizolid Phosphate Tablets for acute bacterial skin and skin structure infections were approved on August 7, 2026.
[Implications for Clinical Trials in India]:
This centralized processing mechanism under the New Drugs and Clinical Trials Rules aims to accelerate therapeutic accessibility while maintaining stringent safety standards for Indian clinical trial participants. Healthcare stakeholders and pharmaceutical developers must prepare documentation in alignment with the revised IND Division mandates before submitting future global trial dossiers.
Pulse Intelligence
Context & ImpactContext & Background
- The Central Drugs Standard Control Organization operates under the New Drugs and Clinical Trials Rules, 2019.
- Phase III Global Clinical Trials involving Indian subjects have become increasingly common for novel therapeutics.
- CDSCO routinely evaluates bulk drug applications and specialized therapeutic formulations.
Key Consequences
- Pharmaceutical companies will experience a more centralized review process for novel drug applications at CDSCO headquarters.
- Clinical research organizations can expect streamlined evaluation timelines for ongoing Phase III global trials.
- Patients will gain faster access to approved specialized treatments like diabetes and skin infection therapies.
Market & Economic Impact
Streamlined CDSCO approvals for novel drugs positively impact pharmaceutical research companies and clinical trial operators.
The Indus Pulse is committed to accuracy and transparency.